As of 2025-12-21, the Relative Valuation of Arrowhead Pharmaceuticals Inc (ARWR) is 4.40 USD. This relative valuation is based on P/E multiples. With the latest stock price at 68.16 USD, the upside of Arrowhead Pharmaceuticals Inc based on Relative Valuation is -93.5%.
The range of the Relative Valuation is (0.21) - 10.59 USD.
| Range | Selected | |
| Trailing P/E multiples | 17.6x - 19.1x | 17.6x |
| Forward P/E multiples | 20.4x - 26.9x | 22.8x |
| Fair Price | (0.21) - 10.59 | 4.40 |
| Upside | -100.3% - -84.5% | -93.5% |
| Date | P/E |
| 2025-12-19 | -5,675.54 |
| 2025-12-18 | -5,534.82 |
| 2025-12-17 | -5,395.76 |
| 2025-12-16 | -5,384.10 |
| 2025-12-15 | -5,699.69 |
| 2025-12-12 | -5,836.25 |
| 2025-12-11 | -5,897.04 |
| 2025-12-10 | -5,734.66 |
| 2025-12-09 | -5,731.33 |
| 2025-12-08 | -5,712.18 |
| 2025-12-05 | -5,115.98 |
| 2025-12-04 | -5,384.10 |
| 2025-12-03 | -5,418.66 |
| 2025-12-02 | -4,825.38 |
| 2025-12-01 | -4,683.82 |
| 2025-11-28 | -4,388.22 |
| 2025-11-26 | -4,805.39 |
| 2025-11-25 | -3,896.11 |
| 2025-11-24 | -3,685.44 |
| 2025-11-21 | -3,368.19 |
| 2025-11-20 | -3,171.68 |
| 2025-11-19 | -3,244.95 |
| 2025-11-18 | -3,369.85 |
| 2025-11-17 | -3,343.21 |
| 2025-11-14 | -3,435.63 |
| 2025-11-13 | -3,425.64 |
| 2025-11-12 | -3,448.96 |
| 2025-11-11 | -3,455.62 |
| 2025-11-10 | -3,318.23 |
| 2025-11-07 | -3,266.60 |
| 2025-11-06 | -3,297.41 |
| 2025-11-05 | -3,356.53 |
| 2025-11-04 | -3,151.69 |
| 2025-11-03 | -3,298.24 |
| 2025-10-31 | -3,529.73 |
| 2025-10-30 | -3,523.07 |
| 2025-10-29 | -3,354.87 |
| 2025-10-28 | -3,293.25 |
| 2025-10-27 | -3,287.42 |
| 2025-10-24 | -3,164.18 |
| 2025-10-23 | -3,110.06 |
| 2025-10-22 | -3,133.37 |
| 2025-10-21 | -3,166.68 |
| 2025-10-20 | -3,203.32 |
| 2025-10-17 | -3,065.09 |
| 2025-10-16 | -3,244.95 |
| 2025-10-15 | -3,180.00 |
| 2025-10-14 | -2,994.31 |
| 2025-10-13 | -3,018.46 |
| 2025-10-10 | -2,948.52 |